Thanks for stating more clearly and professionally what I was getting upset about. Sorry to board and misiu, for too many bourbons, but implications that the company should PR or announce this? I don’t think there is an obligation to supersede the FDA protocol, nor PR a potential clinical addition.

I do think in some cases of PD expression, it would be a tremendous addition to add ICIs. But is Cytodyn obligated to announce this? I think not until it happens, or is updated by FDA. Dr Max’s statement is confusing so far, because it’s not backed up. 50/50 if it’s real, or word salad.